NASDAQ:OVID Ovid Therapeutics Q3 2026 Earnings Results & Report $2.78 -0.08 (-2.63%) As of 03:12 PM Eastern This is a fair market value price provided by Massive. Learn more. Ovid Therapeutics missed analyst earnings expectations in its Q3 2026 results, released November 10, 2026. The company reported EPS of -$0.10 versus the -$0.08 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 10, 2026TimeBefore Market OpensConference Call7:00 AM ET Ovid Therapeutics EPS ResultsActual EPS-$0.10Consensus EPS -$0.08Beat/MissMissed by -$0.02One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersOvid Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$31 thousandBeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsOvid Therapeutics' next earnings date is estimated for Wednesday, November 11, 2026, based on past reporting schedules. Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Ovid Therapeutics Q3 2026 Earnings FAQ Did Ovid Therapeutics beat earnings estimates for Q3 2026? Ovid Therapeutics (NASDAQ:OVID) reported earnings of -$0.10 per share for Q3 2026, missing the consensus estimate of -$0.08. The report was announced on Tuesday, November 10, 2026. When is Ovid Therapeutics' next earnings date? Ovid Therapeutics' next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for Ovid Therapeutics on the company's earnings history page. Ovid Therapeutics Earnings HeadlinesOvid Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 20261 hour ago | marketscreener.comMOvid Therapeutics GAAP EPS of -$0.10 misses by $0.02November 10 at 7:11 AM | seekingalpha.comThe Withdrawal You'll Never See on Your StatementA proposal circulating in Washington, dubbed the Mar-a-Lago Accord, calls for tariffs and currency pressure to deliberately weaken the US dollar, making American exports cheaper. For savers, a weaker dollar can quietly reduce purchasing power even if account balances stay the same. Bishop Gold Group's free 2026 Gold IRA Guide explains how physical gold can be held inside a retirement account, including a common rollover mistake that can trigger a taxable distribution.November 10 at 1:00 AM | Bishop Gold Group (Ad)Ovid Reports $20.8 Million Third-Quarter Net Loss as OV329 AdvancesNovember 10 at 7:10 AM | quiverquant.comQOvid Therapeutics Reports Business Updates and Third Quarter 2026 Financial ResultsNovember 10 at 7:00 AM | globenewswire.comOvid Therapeutics (NASDAQ:OVID) Stock Has Average Target Price of $6.00November 6, 2026 | americanbankingnews.comSee More Ovid Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Ovid Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ovid Therapeutics and other key companies, straight to your email. Email Address About Ovid TherapeuticsOvid Therapeutics (NASDAQ:OVID) Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for epilepsies and other disorders of the central nervous system. The company’s research has concentrated on conditions with significant unmet medical needs, including rare epileptic and neurodevelopmental disorders. Ovid’s pipeline has included soticlestat, an investigational therapy developed in collaboration with Takeda Pharmaceutical Company for developmental and epileptic encephalopathies such as Dravet syndrome and Lennox-Gastaut syndrome. The company has also investigated therapies targeting other neurological conditions, including the former program gaboxadol, which was evaluated for Angelman syndrome and other disorders. Founded in 2014 and headquartered in New York, Ovid has advanced its programs through collaborations with larger pharmaceutical companies and clinical research networks serving patients internationally. Its development strategy has emphasized partnerships intended to support clinical testing, regulatory review and potential commercialization across global markets.View Ovid Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles D-Wave Quantum Has Long-Term Potential, But Is Now the Time to Buy?Archer Aviation's FAA Certificate Is a Milestone, But It Isn't the Final OneDraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Microsoft’s Neocloud Pullback Isn’t a Crack in AI DemandOklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next? Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
